Brazil’s 90-Day Clinical Trial Clock: A Practical Activation Playbook for First-in-Human Studies

For MedTech founders and regulatory leaders, Brazil has quietly become one of the most “plannable” countries in Latin America for early-stage clinical activation. A core reason is Brazil’s recent legal and regulatory modernization, which introduced a defined review window and clearer guardrails for starting studies.

This article translates the change into a sponsor-facing activation playbook: what the 90-business-day clock means, how it interacts with ethics approvals, and what you should build into your timeline to avoid rework. The goal is not to “rush” a trial—it’s to make your activation schedule predictable and audit-ready.

1) What changed in Brazil (and why it matters for FIH planning)

Brazil’s Law No. 14.874/2024 established a national system of ethics in research involving humans and introduced a defined 90-business-day review window for ANVISA’s assessment of clinical trial applications that support marketing authorization.

In practical terms, this is a planning upgrade. Sponsors can build a realistic activation calendar, align manufacturing and logistics windows, and avoid “open-ended” waiting periods that often inflate costs in early-stage programs.

Importantly, Brazil still requires both ethics approval and ANVISA approval before initiation. However, the rules allow parallel submission so you can run key workstreams concurrently rather than serially.

2) The activation sequence: ethics, ANVISA, and parallelization

For most sponsors, the fastest compliant path is a two-track plan:

• Track A (Ethics): prepare site documents, informed consent, investigator materials, and submit to the local ethics committee process.
• Track B (Regulatory): prepare the ANVISA dossier and submit in parallel, ensuring your package is consistent with what ethics committees will see.

A common pitfall is treating ethics and regulatory packages as separate artifacts. Instead, use a single “source of truth” for protocol versioning, risk language, endpoints, and safety reporting workflows.

3) Don’t miss the hidden gating item: the trial-specific dossier

Brazil’s process includes a key practical requirement: ANVISA’s technical analysis of the primary petition may depend on the filing of a trial-specific dossier. That means your internal readiness must include not only the umbrella development dossier, but also at least one trial-specific submission with the minimum documentation set.

Operational takeaway: build your activation plan around “dossier completeness” milestones, not just “submission sent.” Sponsors who plan only to the submission date often discover late-stage gaps in translations, investigational product documentation, or safety reporting alignment.

4) What “decurso de prazo” means (and what it does NOT mean)

Brazil’s reforms also created an important concept often summarized as decurso de prazo: if the health authority does not issue a decision within the legal timeline and the study has the required ethics approvals, clinical development can begin.

For sponsors, this is best treated as a risk-managed backstop rather than a default strategy. Your activation plan should still assume you will operate with an explicit authorization outcome and complete documentation. Use the statutory timeline to reduce uncertainty—not to reduce diligence.

5) A sponsor-ready 90-day activation checklist

If you want to benefit from predictable timelines, your internal systems must be “startup-ready” before the clock runs out. Here is a checklist that consistently prevents avoidable delays:

• Regulatory narrative consistency: protocol synopsis, device/drug description, intended use, and risk statements match across all documents.
• Import and labeling readiness: confirm investigational supply chain steps, packaging needs, and local labeling conventions early.
• Safety workflow: clear SAE reporting path, vendor responsibilities, and escalation coverage (including weekends/holidays).
• Data integrity: eCRF, source templates, and monitoring plan support inspection readiness from Day 1.
• Site enablement: training plan, delegation logs, and equipment calibration records are not afterthoughts.

6) How to use Brazil strategically inside a Latin America multi-country plan

Many early-stage sponsors run a multi-country Latin America strategy to balance speed, cost, and enrollment diversity. Brazil’s clearer timeline can play multiple roles:

• Anchor country: you plan your “first patient in” forecast around a predictable activation window.
• Evidence builder: you generate high-quality data to support later reimbursement or regulatory submissions elsewhere.
• Operational benchmark: you standardize SOPs and monitoring routines that can be replicated across the region.

The key is harmonization: standardize your core protocol and quality system while adapting country-level workflows (ethics requirements, import pathways, and contracting norms).

FAQ

Does Brazil still require ethics approval before starting a clinical trial?

Yes. Sponsors should plan for both ethics and regulatory authorization and use parallel workstreams to compress time without compromising compliance.

Is the 90-business-day period a guarantee that my trial will be approved?

No. It is a defined review window that improves predictability; approval still depends on dossier completeness and meeting regulatory and ethical requirements.

What is the biggest activation mistake sponsors make in Brazil?

Underestimating the time to assemble a trial-specific dossier and align all documents (protocol, consent, IP description, safety reporting). “Submitted” does not equal “complete.”

Bottom line: Brazil’s reform is a planning advantage. Sponsors who pair it with disciplined document control, parallel submission strategy, and site readiness can reduce activation uncertainty—one of the most expensive problems in early-stage trials.